Geode Capital Management
MRVI icon

Geode Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Geode Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5M Buy
3,130,258
+301,663
+11% +$1.3M ﹤0.01% 2172
2026
Q1 		$8.01M Sell
2,828,595
-19,510
-0.7% -$66.1K ﹤0.01% 2499
2025
Q4 		$9.26M Buy
2,848,105
+34,447
+1% +$116K ﹤0.01% 2444
2025
Q3 		$8.08M Sell
2,813,658
-170,387
-6% -$435K ﹤0.01% 2537
2025
Q2 		$7.19M Buy
2,984,045
+319,679
+12% +$672K ﹤0.01% 2545
2025
Q1 		$5.89M Sell
2,664,366
-130,595
-5% -$516K ﹤0.01% 2584
2024
Q4 		$15.2M Buy
2,794,961
+42,884
+2% +$276K ﹤0.01% 2112
2024
Q3 		$22.9M Buy
2,752,077
+162,601
+6% +$1.41M ﹤0.01% 1915
2024
Q2 		$18.5M Buy
2,589,476
+761,564
+42% +$6.57M ﹤0.01% 1966
2024
Q1 		$15.9M Buy
1,827,912
+59,901
+3% +$405K ﹤0.01% 2060
2023
Q4 		$11.6M Buy
1,768,011
+63,109
+4% +$408K ﹤0.01% 2250
2023
Q3 		$17.1M Sell
1,704,902
-56,983
-3% -$626K ﹤0.01% 1926
2023
Q2 		$21.9M Buy
1,761,885
+63,852
+4% +$862K ﹤0.01% 1792
2023
Q1 		$23.8M Buy
1,698,033
+17,511
+1% +$251K ﹤0.01% 1676
2022
Q4 		$24M Buy
1,680,522
+12,436
+0.7% +$196K ﹤0.01% 1649
2022
Q3 		$42.6M Buy
1,668,086
+38,486
+2% +$966K 0.01% 1193
2022
Q2 		$46.3M Buy
1,629,600
+149,020
+10% +$4.72M 0.01% 1186
2022
Q1 		$52.2M Buy
1,480,580
+54,286
+4% +$1.82M 0.01% 1226
2021
Q4 		$59.8M Buy
1,426,294
+90,917
+7% +$3.68M 0.01% 1175
2021
Q3 		$65.5M Buy
1,335,377
+214,221
+19% +$10.4M 0.01% 1046
2021
Q2 		$46.8M Buy
1,121,156
+323,948
+41% +$12.6M 0.01% 1370
2021
Q1 		$28.4M Buy
797,208
+732,770
+1,137% +$24.3M ﹤0.01% 1655
2020
Q4 		$1.81M Buy
+64,438
New +$1.79M ﹤0.01% 3141

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management's MRVI Position: Q2 2026 in Review

Geode Capital Management increased its Maravai LifeSciences (MRVI) stake by 11% in Q2 2026, buying an estimated $1.3M and bringing the position to 3,130,258 shares worth $19.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2172.

Geode Capital Management first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $65.5M in Q3 2021. 162 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Geode Capital Management held 3,130,258 shares of Maravai LifeSciences worth $19.5M as of Q2 2026.
  • Geode Capital Management bought 301,663 Maravai LifeSciences shares in Q2 2026, an estimated $1.3M.
  • Maravai LifeSciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2172 holding.
  • Geode Capital Management first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's Maravai LifeSciences position peaked at $65.5M in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.